CRYSTALLINE FORMS OF CFTR MODULATORS

Crystalline forms of Compound I: Formula (I) pharmaceutically acceptable salts thereof, and solvates and hydrates thereof are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed. L'inv...

Full description

Saved in:
Bibliographic Details
Main Authors ZHOU, Jinglan, MEDEK, Ales, SWIFT, Sara E, HADIDA RUAH, Sara Sabina, PARASELLI, Prasuna, MCCARTNEY, Jason, MILLER, Mark Thomas, FRIEMAN, Bryan, ZWICKER, Carl L, CLEVELAND, Thomas, WALDO, Michael, LU, Jennifer, PIERRE, Fabrice, ANDERSON, Corey Don, LI, Jicong, COON, Timothy Richard, GAGNON, Kevin J, SHI, Yi, ZHANG, Beili, SHRESTHA, Muna, GROOTENHUIS, Peter (deceased), CLEMENS, Jeremy J
Format Patent
LanguageEnglish
French
Published 18.02.2021
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:Crystalline forms of Compound I: Formula (I) pharmaceutically acceptable salts thereof, and solvates and hydrates thereof are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed. L'invention concerne des formes cristallines du composé I de formule (I), des sels pharmaceutiquement acceptables de celles-ci et des solvates et des hydrates correspondants. L'invention concerne également des compositions pharmaceutiques les comprenant, des procédés de traitement de la mucoviscidose à l'aide de celles-ci et des procédés de fabrication de celles-ci.
Bibliography:Application Number: WO2020US46113